Effects_NNS
of_IN
1_CD
alpha_NN
,_,
25-dihydroxyvitamin_NN
D3_NN
on_IN
the_DT
human_JJ
chronic_JJ
myelogenous_JJ
leukemia_NN
cell_NN
line_NN
RWLeu-4_NN
._.

The_DT
effects_NNS
of_IN
1_CD
alpha_NN
,_,
25-dihydroxyvitamin_NN
D3_NN
-LRB-_-LRB-
VD3_NN
-RRB-_-RRB-
on_IN
proliferation_NN
,_,
differentiation_NN
,_,
and_CC
macromolecular_JJ
synthesis_NN
in_IN
the_DT
new_JJ
Philadelphia_NN
chromosome-positive_JJ
chronic_JJ
myelogenous_JJ
leukemia_NN
cell_NN
line_NN
,_,
RWLeu-4_NN
,_,
were_VBD
investigated_VBN
._.

Binding_NN
of_IN
-LCB-_-LRB-
3H-RCB-VD3_CD
was_VBD
saturable_JJ
,_,
with_IN
approximately_RB
2000-3000_CD
sites\/cell_NNS
,_,
and_CC
half-maximal_JJ
binding_NN
occurring_VBG
at_IN
0.21_CD
-0.33_CD
nM_NN
._.

Treatment_NN
of_IN
RWLeu-4_NN
cells_NNS
with_IN
VD3_NN
induced_VBD
24R-hydroxylase_NN
activity_NN
,_,
a_DT
marker_NN
of_IN
vitamin_NN
D3_NN
responsiveness_NN
in_IN
many_JJ
tissues_NNS
._.

Exposure_NN
of_IN
RWLeu-4_NN
cells_NNS
to_TO
VD3_NN
also_RB
inhibited_VBD
proliferation_NN
and_CC
DNA_NN
synthesis_NN
with_IN
a_DT
50_CD
%_NN
effective_JJ
dose_NN
of_IN
3.5-10_CD
nM_NN
within_IN
72_CD
h_NN
;_:
in_IN
addition_NN
,_,
protein_NN
and_CC
RNA_NN
synthesis_NN
were_VBD
inhibited_VBN
by_IN
VD3_NN
treatment_NN
._.

Exposure_NN
of_IN
RWLeu-4_NN
cells_NNS
to_TO
5_CD
nM_NN
VD3_NN
for_IN
72_CD
h_NN
caused_VBD
50_CD
%_NN
of_IN
the_DT
cells_NNS
to_TO
differentiate_VB
into_IN
macrophage\/monocyte_JJ
type_NN
cells_NNS
as_IN
judged_VBN
by_IN
nitroblue_JJ
tetrazolium_NN
staining_NN
and_CC
adherence_NN
to_TO
plastic_NN
._.

Progressive_JJ
expression_NN
of_IN
cell_NN
surface_NN
maturation-specific_JJ
antigens_NNS
of_IN
the_DT
monocyte\/macrophage_NN
lineage_NN
was_VBD
induced_VBN
by_IN
treatment_NN
of_IN
RWLeu-4_NN
cells_NNS
with_IN
VD3_NN
for_IN
24_CD
to_TO
72_CD
h_NN
at_IN
doses_NNS
that_WDT
inhibited_VBD
cellular_JJ
proliferation_NN
._.

c-myc_NN
RNA_NN
,_,
which_WDT
is_VBZ
constitutively_RB
expressed_VBN
in_IN
RWLeu-4_NN
cells_NNS
,_,
increased_VBD
after_IN
0.5_CD
h_NN
of_IN
treatment_NN
with_IN
50_CD
nM_NN
VD3_NN
and_CC
then_RB
rapidly_RB
decreased_VBD
to_TO
barely_RB
detectable_JJ
levels_NNS
after_IN
4_CD
h_NN
of_IN
treatment_NN
._.

Finally_RB
,_,
the_DT
in_FW
vitro_FW
tyrosine_NN
kinase_NN
activity_NN
associated_VBN
with_IN
the_DT
p210bcr-abl_NN
oncogene_NN
product_NN
was_VBD
decreased_VBN
approximately_RB
50_CD
%_NN
by_IN
VD3_NN
treatment_NN
._.

Because_IN
of_IN
the_DT
presence_NN
of_IN
a_DT
functional_JJ
receptor-effector_JJ
system_NN
for_IN
VD3_NN
and_CC
multiple_JJ
biological_JJ
responses_NNS
to_TO
the_DT
hormone_NN
,_,
these_DT
cells_NNS
provide_VBP
a_DT
unique_JJ
model_NN
system_NN
with_IN
which_WDT
to_TO
probe_VB
the_DT
specific_JJ
effects_NNS
of_IN
VD3_NN
on_IN
cell_NN
growth_NN
and_CC
differentiation_NN
in_IN
chronic_JJ
myelogenous_JJ
leukemia_NN
._.

